bone cancer and pain palliation

DESCRIPTION

Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the 2000s. These cancers presented challenges in new drug development partly because of their rarity and heterogeneity. Many new molecular targeting drugs have been tried in the 2010s, and some were approved for bone and soft tissue sarcoma.

The skeleton is a potential metastatic target of many malignant tumors. Up to 85% of prostate and breast cancer patients may develop bone metastases causing severe pain syndromes in many of them. Radionuclide therapy is recommended for pain palliation. The therapy is repeatable, depending on cell counts. Clinical trials using Radium-223 and/or combinations of chemotherapy and radionuclides are aiming at a more curative approach.

Sources:  PubMed

APPROVED TREATMENTS

 ³²P-Sodium Phosphate (bone pain palliation – polycythemia vera)

⁸⁹Sr-Strontium Chloride (bone pain palliation)

¹⁵³Sm-Lexidronam (EDTMP) (bone pain palliation)

¹⁵³Sm-Oxabiphor (ETMP) (bone pain palliation)

¹⁷⁷Lu-EDTMP (bone pain palliation)

¹⁸⁶Re-Rhenium Etidronate (HEDP) (bone pain palliation)

¹⁸⁸Re-Etidronate (HEDP) (pain palliation – RSO)

²²³Ra-Radium Dichloride (bone metastases) 

IN DEVELOPMENT

^177mSn-DTPA (bone pain palliation agent – (Veterinary nuclear medicine drug)) 

PATIENT ASSOCIATIONS

Worldwide: Bone & Cancer Foundation

CLINICAL TRIALS

Bone cancer ¹⁸⁸Re based clinical trials

Bone cancer ¹⁶⁶Ho based clinical trials

Bone cancer ⁸⁹Sr based clinical trials

Bone cancer ¹⁵³Sm based clinical trials

Bone cancer ²²³Ra based clinical trials

*non-exhaustive list

ABOUT BONE CANCER

What is Bone Cancer – American Cancer Society

Bone Cancer (Sarcoma of Bone) – Cancer.Net